baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC TUR.WAR.OP.END. 4AB/ DE000HC71H48 /

13/06/2024 21:41:53	Chg.+0.090	Bid21:59:50	Ask21:59:50	Underlying	Strike price	Expiration date	Option type
5.070EUR	+1.81%	5.070 Bid Size: 30,000	5.080 Ask Size: 30,000	AbbVie Inc	112.1644 USD	31/12/2078	Call

Newsfile Corp 13/06 BioMed X Launches New US Institute in New Haven, CT

GlobeNewswire 13/06 Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...

GlobeNewswire 13/06 LifeSci Advisors Announces Appointment of Chris Howerton Ph.D.

GlobeNewswire 13/06 CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...

GlobeNewswire 13/06 What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...

GlobeNewswire 12/06 US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...

GlobeNewswire 12/06 OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...

GlobeNewswire 11/06 CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urg...

GlobeNewswire 08/06 CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into ...

GlobeNewswire 05/06 CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...

GlobeNewswire 05/06 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

GlobeNewswire 05/06 OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...

GlobeNewswire 04/06 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 04/06 BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

GlobeNewswire 03/06 Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

GlobeNewswire 03/06 ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...

GlobeNewswire 01/06 CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...

GlobeNewswire 30/05 OSE Immunotherapeutics Provides Business and Corporate Update

GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 28/05 Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...

GlobeNewswire 28/05 CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...

GlobeNewswire 28/05 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

GlobeNewswire 25/05 CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...

GlobeNewswire 24/05 Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...

GlobeNewswire 23/05 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...

UC TUR.WAR.OP.END. 4AB/ DE000HC71H48 /

If you wish to receive reply to your feedback, please provide your email address.